FDA Approves Tris Pharma's New Drug Application for Karbinal ER

In continuation of my update on Karbinal (carbinoxamine maleate)...

FDA, has approved its New Drug Application (NDA) for Karbinal ER (carbinoxamine maleate) Extended-release Oral Suspension 4mg/5mL, the first sustained-release histamine receptor blocking agent indicated for the treatment of seasonal and perennial allergic rhinitis in children ages 2 and up.

FDA Approves Tris Pharma's New Drug Application for Karbinal ER

FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids

 Carbinoxamine.........

FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids